2005
DOI: 10.1128/jvi.79.19.12205-12217.2005
|View full text |Cite
|
Sign up to set email alerts
|

Mitochondrial Cell Death Suppressors Carried by Human and Murine Cytomegalovirus Confer Resistance to Proteasome Inhibitor-Induced Apoptosis

Abstract: Human cytomegalovirus carries a mitochondria-localized inhibitor of apoptosis (vMIA) that is conserved in primate cytomegaloviruses. We find that inactivating mutations within UL37x1, which encodes vMIA, do not substantially affect replication in TownevarATCC (Towne-BAC), a virus that carries a functional copy of the betaherpesvirus-conserved viral inhibitor of caspase 8 activation, the UL36 gene product. In Towne-BAC infection, vMIA reduces susceptibility of infected cells to intrinsic death induced by protea… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

19
135
0

Year Published

2007
2007
2012
2012

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 71 publications
(154 citation statements)
references
References 62 publications
(104 reference statements)
19
135
0
Order By: Relevance
“…vMIA protects CMV-infected cells from apoptosis in the late phase of the viral life cycle (Reboredo et al, 2004), and vMIA-deficient/vICA-deficient CMV cannot replicate (because it kills the infected cells prematurely) unless it infects cells that overexpress a Bcl-2-like apoptosis inhibitor (Reboredo et al, 2004). A laboratory strain of vICA-expressing/vMIA-deficient CMV can replicate on human cells (McCormick et al, 2005), but a freshly isolated clinical strain of CMV encoding functionally active vICA loses its replication ability upon knocking out vMIA expression, suggesting that at least in some clinical CMV strains, vMIA is indispensable for viral replication (Jurak and Brune, 2006). The vMIA protein is largely confined to the mitochondrial compartment, where it physically interacts with the protein Bax, recruiting it to mitochondria while neutralizing its proapoptotic function (Arnoult et al, 2004;Poncet et al, 2004).…”
Section: Introductionmentioning
confidence: 99%
“…vMIA protects CMV-infected cells from apoptosis in the late phase of the viral life cycle (Reboredo et al, 2004), and vMIA-deficient/vICA-deficient CMV cannot replicate (because it kills the infected cells prematurely) unless it infects cells that overexpress a Bcl-2-like apoptosis inhibitor (Reboredo et al, 2004). A laboratory strain of vICA-expressing/vMIA-deficient CMV can replicate on human cells (McCormick et al, 2005), but a freshly isolated clinical strain of CMV encoding functionally active vICA loses its replication ability upon knocking out vMIA expression, suggesting that at least in some clinical CMV strains, vMIA is indispensable for viral replication (Jurak and Brune, 2006). The vMIA protein is largely confined to the mitochondrial compartment, where it physically interacts with the protein Bax, recruiting it to mitochondria while neutralizing its proapoptotic function (Arnoult et al, 2004;Poncet et al, 2004).…”
Section: Introductionmentioning
confidence: 99%
“…The HCMV UL36 -38 locus encodes five proteins with antiapoptotic activities, including the predominant UL37 exon 1 protein (pUL37ϫ1), also known as viral mitochondria localized inhibitor of apoptosis (vMIA), the lower abundance UL37 Medium protein and the UL37 glycoprotein, the UL36 protein and the early UL38 protein (9 -12). pUL37ϫ1 blocks mitochondrial-mediated apoptosis by translocating proapoptotic Bax to the outer mitochondrial membrane (OMM) and suppressing its proapoptotic activity (13)(14)(15). In addition, pUL37ϫ1/vMIA has been reported to alter mitochondrial ATP synthesis by decreasing the activity of the mitochondrial phosphate carrier in transfected cells (16).…”
mentioning
confidence: 99%
“…Details of plasmids generated by PCR are reported in Supplementary Table S1 available in JGV Online. LGFP GFPnoSTOP was created by replacing the green fluorescent protein (GFP) ORF in LGFP (McCormick et al, 2005) with a GFP ORF lacking the termination codon TAA. LNCX-mRFP was produced by inserting the monomeric red fluorescent protein (mRFP) ORF amplified by PCR from the pRSET B-mRFP vector (a kind gift from G. Dekaban, Robarts Research Institute, London, ON, Canada) into the BamHI and SalI restriction sites (rs) of LNCX (Miller & Rosman, 1989).…”
Section: Methodsmentioning
confidence: 99%